Site Selection in Europe: Germany, UK, Netherlands Rank High - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Site Selection in Europe: Germany, UK, Netherlands Rank High

Source: Applied Clinical Trials

Against the backdrop of recent statistics showing that applications to run clinical trials in Europe fell 25% between 2007-2011, the SAT-EU study group, an independent non-profit collaborative initiative, supported by the European Forum for Good Clinical Practice (EFGCP) and several other trade and not-for profit organizations, announced the results of a survey, Factors Influencing Clinical Trial Site Selection in Europe: The Survey of Attitudes towards Trial Sites in Europe. Published research based on that survey is now online in the British Medical Journal's BMJ Open.

Apparently, administrative burdens and unhelpful bureaucratic barriers are key deterrents to running clinical trials in Europe, according to the survey, while costs of running trials, as week as any governmental or financial incentives are considered to be of lower importance. “This study seems to indicate that fostering competitiveness of European clinical research may not require additional government spending/incentives. Rather, harmonization of approval processes, greater visibility of centers of excellence, and reduction of hidden indirect costs, may bring significantly more clinical trials to Europe,” commented Ingrid Klingmann, Chairman of the European Forum for Good Clinical Practice (EFGCP).

The research paper also found considerable variability in the perceived receptivity of countries to undertake clinical trials. Germany, the United Kingdom, and the Netherlands were consistently rated the best trial markets, which led authors to suggest a best practice audit of provisions governing clinical trials in these countries would be helpful.

Applied Clinical Trials supported the survey by providing outreach for the collaborative study group survey to our readership.

You can read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here